Methods and compositions for determining lipid peroxidation levels in oxidant stress syndromes and diseases
First Claim
1. A method of measuring the level of lipid peroxidation in a mammal suspected of having an oxidant stress syndrome or disease, wherein said oxidant stress syndrome or disease is Alzheimer'"'"'s disease, said method comprisinga) obtaining a first sample of a tissue or body fluid from said mammal;
- b) assessing the level of an isoprostane molecular marker for lipid peroxidation present in said first sample, wherein said isoprotane molecular marker is selected from the group consisting of iPF2α
-III, iPF2α
-VI, and 8,12-iso-iPF2α
-VI; and
c) comparing the level of said isoprostane molecular marker present in said first sample with the level of said isoprostane molecular marker present in a second sample of a tissue or body fluid obtained from an otherwise identical mammal which is not afflicted with an oxidant stress syndrome or disease, wherein an elevated level of said isoprostane molecular marker in said first sample relative to the level of said isoprostane molecular marker in said second sample, is indicative of an elevated level of lipid peroxidation in said mammal, thereby indicating the presence of an oxidant stress syndrome or disease in said mammal.
4 Assignments
0 Petitions
Accused Products
Abstract
The invention includes methods useful for the diagnosis of Alzheimer'"'"'s disease and the evaluation of enhanced levels of lipid peroxidation in a mammal. The methods utilize isoprostanes as sensitive and stable molecular markers for lipid peroxidation in a mammal. Methods of identifying compounds useful for the treatment of Alzheimer'"'"'s disease or for reducing levels of lipid peroxidation in a mammal are also included. The invention also includes kits useful for the diagnosis of Alzheimer'"'"'s disease and for the evaluation of levels of lipid peroxidation in a mammal.
31 Citations
32 Claims
-
1. A method of measuring the level of lipid peroxidation in a mammal suspected of having an oxidant stress syndrome or disease, wherein said oxidant stress syndrome or disease is Alzheimer'"'"'s disease, said method comprising
a) obtaining a first sample of a tissue or body fluid from said mammal; -
b) assessing the level of an isoprostane molecular marker for lipid peroxidation present in said first sample, wherein said isoprotane molecular marker is selected from the group consisting of iPF2α
-III, iPF2α
-VI, and 8,12-iso-iPF2α
-VI; and
c) comparing the level of said isoprostane molecular marker present in said first sample with the level of said isoprostane molecular marker present in a second sample of a tissue or body fluid obtained from an otherwise identical mammal which is not afflicted with an oxidant stress syndrome or disease, wherein an elevated level of said isoprostane molecular marker in said first sample relative to the level of said isoprostane molecular marker in said second sample, is indicative of an elevated level of lipid peroxidation in said mammal, thereby indicating the presence of an oxidant stress syndrome or disease in said mammal. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8)
-
-
9. A method of diagnosing an oxidant stress syndrome or disease in a mammal, wherein said oxidant stress syndrome or disease is Alzheimer'"'"'s disease, said method comprising
a) obtaining a first sample of a tissue or body fluid from said mammal; -
b) assessing the level of said isoprostane molecular marker present in said first sample; and
wherein said isoprotane molecular marker is selected from the group consisting of iPF2-III, iPF2α
-VI, and 8,12-iso-iPF2α
-VI; and
c) comparing the level of said isoprostane molecular marker present in said first sample with the level of said isoprostane molecular marker present in a second sample of a tissue or body fluid obtained from an otherwise identical mammal which is not afflicted with said oxidant stress syndrome or disease, wherein an elevated level of said isoprostane molecular marker in said first sample relative to the level of said isoprostane molecular marker in said second sample, is indicative of an elevated level of lipid peroxidation in said mammal, whereby said oxidant stress syndrome or disease is diagnosed in said mammal. - View Dependent Claims (10)
-
-
11. A method of measuring the level of an isoprostane molecular marker for lipid peroxidation in a mammal suspected of having an oxidant stress syndrome or disease, said method comprising
a) obtaining a sample of a tissue or body fluid from said mammal; -
b) isolating from said sample said isoprostane molecular marker by using a total lipids solvent extraction method; and
c) quantifying the level of said isoprostane molecular marker. - View Dependent Claims (12, 13, 14, 15, 16, 17)
-
-
18. A method of identifying a compound useful for the treatment of Alzheimer'"'"'s disease in a mammal, said method comprising
a) measuring the level of an isoprostane molecular marker for lipid peroxidation in either a sample of a tissue or body fluid obtained from a first mammal prior to administering said compound, or, in a sample of a tissue or body fluid obtained from an otherwise identical second mammal which is not to be administered said compound; -
b) administering said compound to said first mammal;
c) thereafter measuring the level of said isoprostane molecular marker in a tissue or body fluid obtained from said first mammal; and
d) comparing the level of said isoprostane molecular marker measured in c) with the level of said isoprostane molecular marker measured in a), wherein when the level of said isoprostane molecular marker measured in c) is reduced relative to the level of said isoprostane molecular marker measured in a), a compound useful for the treatment of Alzheimer'"'"'s disease in a mammal is identified. - View Dependent Claims (19, 20, 21)
-
-
22. A method of identifying an effective amount of a compound useful for the treatment of Alzheimer'"'"'s disease in a mammal, said method comprising
a) measuring the level of an isoprostane molecular marker for lipid peroxidation in either a sample of a tissue or body fluid obtained from a first mammal prior to administering said compound, or, in a sample of a tissue or body fluid obtained from an otherwise identical second mammal which is not to be administered said compound; -
b) administering to said first mammal an amount of said compound;
c) thereafter measuring the level of said isoprostane molecular marker in a tissue or body fluid obtained from said first mammal; and
d) comparing the level of said isoprostane molecular marker measured in c) with the level of said isoprostane molecular marker measured in a), wherein when the level of said isoprostane molecular marker measured in c) is reduced relative to the level of said isoprostane molecular marker measured in a), an effective amount of a compound useful for the treatment of Alzheimer'"'"'s disease in a mammal is identified.
-
- 23. A method of determining the optimal concentration of a compound useful for the treatment of Alzheimer'"'"'s disease, said method comprising monitoring the level of an isoprostane molecular marker for lipid peroxidation in a series of mammals administered said compound at a series of concentrations of compound, wherein the concentration of said compound which results in maximal reduction of the level of said isoprostane molecular marker in one or more of said series of mammals, which concentration is not toxic to said mammals, is said optimal concentration.
-
26. A method of determining the optimal dosage frequency of a compound useful for the treatment of Alzheimer'"'"'s disease, said method comprising monitoring the level of an isoprostane molecular marker for lipid peroxidation in a series of mammals administered said compound at a series of dosage frequencies, wherein the dosage frequency of said compound which results in maximal reduction of the level of said isoprostane molecular marker in one or more of said series of mammals, which dosage is not toxic to said mammals, is said optimal dosage frequency.
-
27. A method of identifying a compound useful for reducing the level of an isoprostane molecular marker for lipid peroxidation in a sample of a tissue or body fluid obtained from a first mammal, said method comprising
a) measuring the level of said isoprostane molecular marker in either a sample of a tissue or body fluid obtained from said first mammal prior to administering said compound, or, in a sample of a tissue or body fluid obtained from an otherwise identical second mammal which is not to be administered said compound; -
b) administering said compound to said first mammal;
c) thereafter measuring the level of said isoprostane molecular marker in a tissue or body fluid sample obtained from said first mammal;
d) comparing the level of said isoprostane molecular marker measured in c) with the level of said isoprostane molecular marker measured in a), wherein when the level of said isoprostane molecular marker measured in c) is reduced relative to the level of said isoprostane molecular marker measured in a), a compound useful for reducing the level of an isoprostane molecular marker in a mammal is identified. - View Dependent Claims (28, 29, 30)
-
-
31. A kit for diagnosing Alzheimer'"'"'s disease in a mammal, said kit comprising
a) a sample container for carrying a tissue or body fluid sample from said mammal; -
b) a solution for use in extraction of an isoprostane molecular marker for lipid peroxidation from said tissue or body fluid sample obtained from said mammal;
c) a negative control solution of said isoprostane molecular marker of lipid peroxidation present at a concentration of about the concentration of said isoprostane molecular marker present in a tissue or body fluid sample of a mammal which is not afflicted with Alzheimer'"'"'s disease;
d) a positive control solution of said isoprostane molecular marker of lipid peroxidation present at a concentration of about the concentration of said isoprostane molecular marker in a tissue or body fluid sample of a mammal which is afflicted with Alzheimer'"'"'s disease;
e) an antibody directed against an isoprostane molecular marker for lipid peroxidation; and
f) an instructional material.
-
-
32. A kit for measuring the level of an isoprostane molecular marker for lipid peroxidation in a tissue or body fluid sample obtained from a mammal, said kit comprising
a) a sample container for carrying a tissue or body fluid sample from said mammal; -
b) a solution for use in extraction of an isoprostane molecular marker of lipid peroxidation from said tissue or body fluid sample obtained from said mammal;
c) a negative control solution of said isoprostane molecular marker of lipid peroxidation present at a concentration of about the concentration of said isoprostane molecular marker present in a tissue or body fluid sample of a mammal which is not afflicted with Alzheimer'"'"'s disease;
d) a positive control solution of said isoprostane molecular marker of lipid peroxidation present at a concentration of about the concentration of said isoprostane molecular marker in a tissue or body fluid sample of a mammal which is afflicted with Alzheimer'"'"'s disease;
e) an antibody directed against an isoprostane molecular marker for lipid peroxidation; and
f) an instructional material.
-
Specification